Povorcitinib (phosphate)

Povorcitinib (INCB54707) phosphate is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib phosphate can be used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) (information extracted from patent WO2021076124A1) [1].

Product Specifications

CAS Number

[1637677-33-8]

Product Name Alternative

INCB54707 (phosphate)

UNSPSC

12352005

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/povorcitinib-phosphate.html

Purity

98.82

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=P(O)(O)O.N#CCC1(N2C=C(C3=C(C)NN=C3C)C=N2)CN(C4=C(C=C(C(F)=C4)C(N[C@@H](C)C(F)(F)F)=O)F)C1

Molecular Formula

C23H25F5N7O5P

Molecular Weight

605.45

References & Citations

[1]Paul Smith, et al. Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) . Patent WO2021076124A1.|[2]Kirby JS, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2023 Oct 21:S0190-9622 (23) 03037-2.|[3]Zouboulis C C, et al. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment[J]. Journal of the European Academy of Dermatology and Venereology, 2024.|[4]Tuttle KD, et al., JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. Cell Rep. 2020 Nov 17;33 (7) :108407.